The impact of openMedicine findings for standardization

Giorgio Cangioli - HL7 Int. Foundation

OpenMedicine Workshop
20th December, 2016
Swedish eHealth Agency, Stockholm
The choice...

ISO Identification of Medicinal Products (IDMP) Standards
What is needed?

• IDMP attributes and identifiers have to be **timely available** to "end users" systems.

![BPMN Diagram]

Legend:
- Green: Standards available or under definition
- Yellow: Guidance and/or Updates needed
- Red: Missing Standards

- Clinical Information Systems
- Pharmacovigilance
- EMA
- Product Discovery
- National Agency
- Manufaturer
- (National) MPD Discovery
- (Local) MPD Discovery
- (IDMP) Product Discovery
- MPD Provider
- National Agencies may act as MPD provider
- Data Exchange

---

openMedicine Workshop @eHälsomyndighetens, Stockholm(SE) 1/23/2017 • 3
What is needed?

- IDMP attributes and identifiers have to be timely available to “end users” systems.

There are HL7 Project Proposals (PSSs) with several WGs involved to work on communication about products between Agency / MPD provider and Clinical Systems.
What about the other standards?

- What is the impact on other HL7 products e.g. HL7 V2, FHIR, other HL7 V3 messaging or services, CDA templates;..

- What does it mean to use IDMP out of the regulatory use cases
  - Just use few IDMP identifiers?
  - To comply with the IDMP model (or a subset of it) [model to model mapping]
  - Use “IDMP terminologies”?

- What should be the migration path?
  - What of the IDMP can be used and when
  - What products under development (e.g. IPS) should do?
openMedicine & (I)PS

A common intent...

International Patient Summary......

JIC Standard Sets

HL7 IPS Project [aka INTERPAS]

CEN/TC 254 IPS Project

...a single "project"... conducted by several organizations...

...with "informal" coordination... the alignment process continues...

openMedicine Workshop @eHälsomyndigheten, Stockholm(SE)
CEN/HL7 IPS

• Common scope for the CEN and HL7 IPS project:
  • “Minimal and non-exhaustive Patient Summary, specialty-agnostic, condition-independent, but readily usable by all clinicians for the unscheduled (cross-border) care of a patient.”

• Principles for the standards specification for the IPS:
  o implementable
  o applicable for (free) global use
  o sustainable
openMedicine & (I)PS

IDMP
- Products
  - PhPID
  - MPID, PCID
- Substances
  - G-SRS
- Dose form, RoA, ...
  - EDQM
- ...

openMedicine

eHDSI

IPS

Allergies & Intolerances

Medication Summary

Product

Product class

Substances

PhPID

MPID, PCID

G-SRS

EDQM

openMedicine Workshop @eHälsomyndigheten, Stockholm(SE) 1/23/2017
openMedicine & (I)PS

IDMP
- Products
- Substances
- Dose form, RoA, ...
- ...
- MPID, PCID
- G-SRS
- EDQM

openMedicine

eHDSI

IPS
openMedicine & (I)PS

**hypothesis**
- Under Discussion
  - UNII
  - XEVMPD
  - G-SRS
  - Local
  - Global (now)
  - Global (future)

- **IPS**
  - implementable
  - applicable for (free) global use
  - sustainable

**openMedicine**
- Products
  - PhPID, ...
- Substances
  - G-SRS
- Dose form, RoA, ...
  - EDQM

**Beyond eHDSI**
- ATC
  - XEVMPD (?)
  - G-SRS

**eHDSI**

---

openMedicine Workshop @eHälsomyndigheten, Stockholm(SE)

1/23/2017
openMedicine & (I)PS

- Implementable
- Applicable for (free) global use
- Sustainable

**Hypothesis**

- Local Codes
- PhPID, MPID, ...

- Beyond eHDSI

**OpenMedicine**

- Product name

**Under Discussion**

- RxNorm
- Global (now)
- Local
- Global (future)

**IPS**

**Future Version**

openMedicine Workshop @eHälsomyndigheten, Stockholm(SE)

1/23/2017
Medicines data are represented in CDA using the class `manufacturedMaterial`

A **code** and a **name** that can be used for any level of product: packaged product, medicinal product, classes or clusters or products,..

Not enough for IDMP! Extensions are needed

**HL7 IPS**: not rely on IDMP identifiers and attributes, but be open for supporting at least the IDMP identifiers
openMedicine & (I)PS

- eHDSI
  - describe medicines...

- openMedicine
  - .. to IDMP..

- IPS
  - .. IDMP ready..

Extension based on the HL7 R_Medication CMET

Proposal to update the extension with HL7 Common Product Model CMET (that used in the SPL for the IDMP implementation Guide)

[under discussion] Refer to HL7 CPM CMET to be provide future support to IDMP
Take-away questions..

• How the results of openMedicine can be used with a view to the transitional phase?

• What are the implications of potential different choices for substances (e.g. XEVMPD versus SNOMED CT) while waiting for a global identifier (G-SRS)?

• How the eHDSi and the IPS work can be kept aligned among them and with the (current and future) openMedicine work?
  o Substances
  o CDA Implementation (e.g. R_Medication vs CPM)
That's all Folks!